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Abstract: Consisting of a silica core surrounded by a thin gold shell, nanoshells possess an   
optical tunability that spans the visible to the near infrared (NIR) region, a region where 
light penetrates tissues deeply. Conjugated with tumor-specific antibodies, NIR-absorbing 
immunonanoshells can preferentially bind to tumor cells. NIR light then heats the bound 
nanoshells, thus destroying the targeted cells. Antibodies can be consistently bound to the 
nanoshells via a bifunctional polyethylene glycol (PEG) linker at a density of ~150 antibodies 
per nanoshell. In vitro studies have confirmed the ability to selectively induce cell death with 
the photothermal interaction of immunonanoshells and NIR light. Prior to incubation with 
anti-human epidermal growth factor receptor (HER2) immunonanoshells, HER2-expressing 
SK-BR-3 breast carcinoma cells were seeded alone or adjacent to human dermal fibroblasts 
(HDFs). Anti-HER2 immunonanoshells bound to HER2-expressing cells resulted in the death 
of SK-BR-3 cells after NIR exposure only within the irradiated area, while HDFs remained 
viable after similar treatment since the immunonanoshells did not bind to these cells at high 
levels. Control nanoshells, conjugated with nonspecific anti-IgG or PEG, did not bind to either 
cell type, and cells continued to be viable after treatment with these control nanoshells and 
NIR irradiation. 
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Introduction
Metal nanoshells are optically tunable nanoparticles, consisting of a spherical dielectric 
core encapsulated by a thin metal shell. The overall particle size as well as the ratio of 
core radius to shell thickness dictates the scattering and absorbing properties of the 
particle. For a given core radius, decreasing the shell thickness (increasing the core:
shell ratio) shifts the peak plasmon resonance to longer wavelengths (Oldenburg et 
al 1998; Averitt et al 1999). The resonance tunablity spans the visible and infrared 
spectrum (Averitt et al 1999). By placing the peak absorption properties in the near 
infrared (NIR) region where tissue absorption is at a minimum (Welch and van Gemert 
1995; Weissleder 2001), nanoshells within tissue can preferentially absorb NIR light 
energy. 
Nanoshell photothermal cancer therapy works through the preferential accumulation 
of nanoshells in a tumor and absorption of NIR light by those particles to locally 
generate heat at the tumor site. Nanoshells have been shown to passively accumulate 
in tumors after intravenous injection (O’Neal et al 2004) as a result of the leaky 
vasculature characteristic of neoplastic tumors (Hashizume et al 2000). After systemic 
injection and accumulation at the tumor site, NIR light is applied over the tumor region. 
The absorbed energy causes the nanoshells to heat, allowing local destruction of the 
tumor tissue. In a mouse model, nanoshell-treated tumors completely regressed after 
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the nanoshell therapy experienced rapid temperature rises 
sufficient to cause irreversible tissue damage, while laser 
application to nearby healthy tissue or to tumors not treated 
with nanoshells did not induce a significant temperature 
increase (Hirsch et al 2003). 
Molecularly targeting nanoshells to tumors via antibodies 
against cell surface markers may further enhance the 
accumulation of nanoshells in tumors, prolong their presence 
in tumors, and potentially allow the use of lower nanoshell 
dosages. Many tumors have increased expression of specific 
cell surface markers. Several markers have been investigated 
for targeting applications, including human epidermal growth 
factor receptor (HER2) (Wu et al 2003), αv integrin (Arap et 
al 1998; Anderson et al 2000; Reynolds et al 2003), and CD44 
(Verel et al 2002). These targets have been used to deliver 
genes (Reynolds et al 2003), chemotherapeutics (Backer and 
Backer 2001), and nanoparticles (Anderson et al 2000; Wu 
et al 2003). Antibody targeting of nanoparticles and drugs   
to tumors has shown increased delivery of therapeutic   
agents (Tarli et al 1999; Cortez-Retamozo et al 2002; 
Reynolds et al 2003). Specifically, the human epidermal 
growth factor receptor HER2 has been used to target 
breast cancer cells because of its stable overexpression on 
~30% of breast cancers (Slamon et al 1989; McDermont 
et al 2002; Kämmerer et al 2003; Carlsson et al 2004). 
Using HER2 targeted immunoliposomes, the uptake of 
the chemotherapeutic drug doxorubicin was increased 
700-fold (Park et al 2001, 2002; Noble et al 2004). In the 
current studies, antibody conjugation to nanoshells has 
been evaluated, and nanoshells conjugated with anti-HER2 
are investigated for targeting nanoshell binding to HER2-
expressing breast carcinoma cells. 
Materials and methods
Synthesis of polyethylene (PEG) thiol 
(PEG-SH)
PEG-SH was synthesized by reacting PEG-amine (Mr 5000, 
Nektar, Huntsville, AL, USA) with 2-iminothiolane (Sigma-
Aldrich, St Louis, MO, USA) for 1 hour. The product was 
dialyzed (molecular weight cutoff of 500 Da; Spectrum 
Laboratories, Rancho Domingo, CA, USA) against deionized 
(DI) water for at least 4 hours to remove excess reagents. 
The PEG-SH yield was determined colorimetrically at 
412 nm after reacting with Ellman’s reagent, 5,5'-dithio-





xysuccinimide ester (OPSS-PEG-NHS, 2000 Da) was 
obtained from Nektar (San Carlos, CA, USA) in lyophilized 
form. C-erbB-2/HER2/neu Ab-4 (clone N12) (anti-HER2) 
was obtained from NeoMarkers (Fremont, CA, USA). A 
81 µmol/L (0.16 mg/mL) solution of OPSS-PEG-NHS was 
mixed with 5.4 µmol/L (1 mg/mL) anti-HER2 at a volumetric 
ratio of 1:9 and reacted at 4
oC overnight. 
Nanoshell synthesis
Nanoshells were synthesized as previously described 
(Oldenburg et al 1998; Averitt et al 1999). Briefly, silica 
nanoparticles were fabricated by the Stöber method (Stöber 
et al 1968) in which tetraethyl orthosilicate is reduced in 
basic ethanol. The surfaces of the silica particles were reacted 
with aminopropyl triethoxysilane, terminating the surface 
with amine groups. Small gold colloid (~3 nm), prepared 
by the method of Duff et al (1993), was then adsorbed onto 
the nanoparticle surface. The adsorbed colloid was used as 
nucleation sites for reduction of additional gold onto the 
surface to generate a contiguous shell of gold. Nanoshells 
were evaluated by their optical absorption profiles using a 
Cary 50 BIO UV Vis spectrophotometer and size distribution 
under scanning electron microscopy (XL30, Philips Electron 
Optics, Netherlands). The nanoshells used in the following 
study had a 110 nm core diameter with an 11 nm thick gold 
shell and peak extinction at ~820 nm. 
Nanoshell anti-HER2 conjugation
PEG-conjugated anti-HER2/neu (0.9 mg/mL) was added 
to 8.8x10
8 nanoparticles/ml (absorption=1.5 at 800 nm at 
1 cm path length) to obtain a final antibody concentration 
of 7.5 µg/mL. The suspension was reacted at 4
oC overnight. 
A 0.05 mM PEG-SH solution was added to the nanoshells 
at a volume ratio of 9 parts nanoshells:1 part PEG-SH and 
reacted at 4
oC overnight. Immunonanoshells were divided 
as 1 mL aliquots into 2.0 mL eppendorf tubes (Sigma-
Aldrich). The aliquots were centrifuged at 500 g for 5 min 
(Eppendorf Centrifuge 5415C). Immediately, the supernatant 
was removed and aliquots were resuspended in McCoy’s 5a 
medium supplemented with 10% fetal bovine serum (FBS), 
1.8 mM L-glutamine, 90 units/mL penicillin, and 0.9 µg/mL 
streptomycin to obtain a final nanoshell concentration of 
2.9x10
9 particles/mL (absorption = 5 at 800 nm at a 1 cm 
path length). International Journal of Nanomedicine 2006:1(2) 151
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Quantification of the number of 
antibodies per nanoshell (ELISA) 
Immunonanoshells were incubated with horseradish 
peroxidase-labeled (HRP) anti-mouse IgG (Sigma-Aldrich, 
A3682) for 1 hour. Nonspecific reaction sites were blocked 
with a 3% solution of bovine serum albumin (BSA). 
Nanoshells were rinsed to remove any unbound IgG. The HRP 
bound to the immunonanoshells was reacted with 3,3',5,5'-
tetramethylbenzidine to generate a colored product and 
compared with a HRP anti-mouse IgG standard curve ranging 
from 7x10
–6 to 7x10
–9g/ml. Results were read using a spectro-
photometer (Cary BIO 50, Varian, CA, USA) at 450 nm. 
Imaging of antibodies bound to 
nanoshells
Immunonanoshells, prepared as described above, were 
incubated with gold-labeled anti-mouse IgG (Molecular 
Probes, Eugene, OR, USA) for 1 hour. Nonspecific reaction 
sites were blocked with a 3% solution of BSA. Nanoshells 
were rinsed to remove any unbound IgG. Samples were 
mounted on copper grids and imaged with a JEOL 2010 
transmission electron microscope (TEM, JEOL Ltd., 
Japan). 
Cell maintenance
Chemicals were obtained from Sigma-Aldrich unless 
otherwise stated. SK-BR-3 breast carcinoma cells were 
obtained from American Type Culture Collection (ATCC, 
Manassas, VA, USA). Cells were maintained in McCoy’s 5a 
medium supplemented with 10% FBS, 1.8 mM L-glutamine, 
90 units/mL penicillin, and 0.9 µg/mL streptomycin. MCF-7 
breast carcinoma cells (HER2 negative) were obtained from 
ATCC and maintained in Eagle’s Minimal Essential Medium 
supplemented with 10% FBS, 1.8 mM L-glutamine, 90 
units/mL penicillin, 0.9 µg/mL streptomycin, and 0.01 mg/
mL bovine insulin. Human dermal fibroblasts (HDFs) were 
obtained from ATCC and maintained in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% FBS, 
1.8 mM L-glutamine, 90 units/ml penicillin, and 0.9 µg/ml 
streptomycin. Cells were incubated at 37
oC in a 5% CO2 
environment. For monoculture experiments, cell were seeded 
into 24-well trays at 1x10
4 cells/cm
2 and cultured to near 
confluency. For side-by-side co-culture experiments, where 
2 cell types were located adjacent to one another, each cell 
type was grown separately on glass cover slips coated in 1% 
gelatin. Immediately prior to nanoshell incubation, 2 cover 
slips containing different cell types were aligned such that 
the cover slips set side-by-side on a glass-chambered slide 
without a gap separating them. 
Photothermal destruction of cells 
incubated with immunonanoshells 
Cells were rinsed 3 times in phosphate buffered saline (PBS, 
pH 7.4). Nanoshells were mixed with 10x McCoy’s 5A 
medium without FBS at a ratio of 9:1. 500 µl of nanoshell 
suspension was added to the cell cultures. Cells were returned 
to the 37
oC incubator for 45 minutes. Following incubation, 
cells were rinsed 3 times in PBS and then covered in McCoy’s 
5A medium. Cells were exposed to NIR laser irradiation 
(Coherent, 820 nm, 0.8 W/m
2 for 7 min) and then returned 
to the 37
oC incubator overnight. 
Silver staining to evaluate nanoshell 
binding 
Cells were fixed with a 2.5% formalin solution for 10 
minutes then rinsed 3 times with DI water. A silver staining 
kit (Amersham Biosciences, Piscataway, NJ, USA) was 
used to stain cells, depositing silver onto the gold nanoshell 
surfaces, to allow visualization of nanoshell binding to cells 
via light microscopy.
Viability staining
A Live/Dead Stain Kit (calcein AM and ethidium homodimer, 
Molecular Probes, CA, USA) was used to evaluate cell 
viability after NIR treatment. Cells were then examined by 
fluorescence microscopy (Ziess Axiovert 135, Thornwood, 
NY, USA).   
Results
Quantification and imaging of 
antibodies on nanoshells
The anti-HER2 conjugated nanoshells bound a significant 
number of antibodies compared with PEG-coated nanoshells 
(p<0.05). Each immunonanoshell was conjugated with 
152±128 anti-HER2 antibodies. The ELISA-style assay 
confirmed that no antibodies were present on the nanoshells 
coated with PEG only (–16±19 antibodies/nanoshell). In the 
TEM image of the nanoshell (Figure 1), the binding of the 
gold colloid-labeled secondary antibody can be clearly seen. 
Additionally, the visualization of antibody conjugation is in 
good agreement with the quantification achieved using the 
ELISA-style assay. International Journal of Nanomedicine 2006:1(2) 152
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Photothermal destruction of  
mono-cultured cells incubated with 
immunonanoshells 
Anti-HER2 conjugated nanoshells associated specifically 
with HER2 expressing cells at sufficient concentrations such 
that the combination of nanoshells and NIR light-induced cell 
death. Anti-HER2 conjugated nanoshells bound to the SK-
BR-3 cell surface, as seen in the silver stain image (Figure 
2f), and induced cell death within the laser exposure area, 
as seen in the viability stain (Figure 2c). Incubation of SK-
BR-3 cells with nanoshells conjugated with a non-specific 
anti-IgG (Figure 2a, d) or with PEG alone (Figure 2b, e) did 
not facilitate the binding of the nanoshells to the cell surface. 
Anti-HER2 conjugated nanoshells did not bind to MCF-7 
cells, which do not express HER2. 
Photothermal destruction of targeted 
cells in co-culture 
In Figure 3, where the two cell types were adjacent to one 
another, only cells within the laser spot and of the targeted 
cell type were destroyed by the treatment. The HDFs, also 
exposed to the NIR light, did not die. When co-cultures 
were incubated with PEG-coated nanoshells (Figure 3b), 
both cell types remained viable after laser irradiation. Only 
the HER2-expressing SK-BR-3 cells bound with anti-HER2 
immunonanoshells and irradiated with NIR laser died. 
Discussion
The anti-HER2 conjugated nanoshells bound a significant 
number of antibodies. The density of ~152 anti-HER2 
antibodies per immunonanoshell exceeded that obtained on 
immunoliposomes of similar size, where 30–50 antibodies 
per liposome were achieved (Cerletti et al 2000; Park et al 
2002). The ELISA-style data are supported by the TEM 
images (Figure 1) where the gold-labeled secondary antibody 
bound to the anti-HER2 antibody speckles the outer surface 
of the conjugated nanoshell. TEM imaging and the ELISA 
Figure 1  Transmission electron micrograph of an immunonanoshell with gold-
labeled antibodies (example indicated by arrow) shows several antibodies bound 
to the nanoshell surface within the hazy polyethylene glycol (PEG) layer. 
Figure 2  Antibody conjugated nanoshells bound to cells when the appropriate antigen was present. SK-BR-3 cells were incubated with PEG-coated nanoshells (a, d), 
anti-IgG conjugated nanoshells (b, e), and anti-HER2 conjugated nanoshells (c, f). Following laser exposure, a region of cell death corresponding to the laser spot resulted in 
groups incubated with anti-HER2 conjugated nanoshells (c). Cells incubated with PEGylated or anti-IgG conjugated nanoshells continued to live. Silver staining (d–f) showed 
maximal binding of anti-HER2 conjugated nanoshells to the SK-BR-3 cells (f). Laser spot is 1.5 mm wide.
Abbreviations: HER2, epidermal growth factor receptor; PEG, polyethylene glycol.International Journal of Nanomedicine 2006:1(2) 153
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assay confirmed that no antibodies were present on the 
nanoshells coated with PEG only. 
Anti-HER2 conjugated immunonanoshells bound to 
the SK-BR-3 cell surface and induced cell death within the 
laser exposure area. Anti-HER2 nanoshells did not bind to 
MCF-7 cells, which do not express HER2. Incubation of 
SK-BR-3 cells with nanoshells conjugated with a nonspecific 
anti-IgG or with PEG alone did not facilitate the binding of 
the nanoshells to the cell surface. As previously seen, cell 
death requires the simultaneous exposure of cells to both 
nanoshells and NIR light (Hirsch et al 2003; Loo et al 2004, 
2005). Nonspecific anti-IgG nanoshells and PEG nanoshells, 
not bound to cell surfaces, were rinsed away during washing 
thus preventing cell death after NIR irradiation.   
The cellular specificity of the nanoshell treatment 
achieved through the addition of the antibody was verified 
in the co-culture experiments. In Figure 3, where the SK-
BR-3 cells and HDFs were adjacent to one another, only 
cells within the laser spot and of the targeted cell type died. 
NIR light was applied to the co-culture overlapping both 
cell types simultaneously. An area of cell death resulted only 
on the targeted SK-BR-3 cells incubated with anti-HER2 
immunonanoshells. When co-cultures were incubated with 
PEG-coated nanoshells, both cell types continued to live 
after laser irradiation. Only the HER2-expressing cells bound 
with anti-HER2 immunonanoshells and irradiated with the 
NIR laser died, even when they were in close proximity to 
nontargeted healthy cells. 
The in vitro studies detailed here demonstrate the ability 
of the immunonanoshells to bind specifically and to facilitate 
the thermal therapy locally on an individual cell level. Within 
tumors, the active binding of nanoshells will increase the 
accumulation by promoting longer retention times in the 
tumor. The incorporation of an antibody onto the nanoshell 
surface should increase the uptake within targeted tissues 
in vivo. 
Conclusions
The addition of a tumor-specific antibody should increase 
the specificity of the nanoshell therapy, as indicated by these 
initial in vitro results. Immunonanoshells bind to targeted 
cells whether the cells are alone or adjacent to healthy 
cells. Upon laser irradiation, the cells bound by nanoshells 
are killed, leaving the healthy cells unharmed. Successful 
treatments not only require the laser and nanoshells to be 
present simultaneously, but in order for nanoshells to be 
present in vitro, they must actively bind to the targeted cell 
type. In vivo, the accumulation of immunonanoshells within 
a tumor will not simply rely on the enhanced permeability 
of tumors as previously demonstrated (O’Neal et al 2004). 
In addition to utilizing the elevated permeability of tumors, 
the ability of immunonanoshells to bind tumor cells should 
further promote the localization of nanoshells within the 
tumor. The increased specificity by the antibodies has 
tailored the immunonanoshell for higher accumulations at 
targeted tissues and thus improved the nanoshell therapeutic 
efficiency. 
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Figure 3  Two cell types, SK-BR-3 (left side of a and b) and HDF (right side of a and b) cells, were grown on glass cover slip and aligned as shown prior to the experiment. 
(a) Anti-HER2 immunonanoshells bound to the HER2 expressing SK-BR-3 cells resulted in targeted cell death after laser irradiation. The laser area is outlined in white.  
(b) Nanoshells coated in PEG only did not bind cells and laser irradiation produced no area of cell death. Laser spot is 2.5 mm wide.
Abbreviations: HDF, human dermal fibroblasts; HER2, epidermal growth factor receptor; PEG, polyethylene glycol.International Journal of Nanomedicine 2006:1(2) 154
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